1. Academic Validation
  2. Environmental Chemical-Induced Cardiometabolic Disorders: Combined Epidemiological and Experimental Evidence

Environmental Chemical-Induced Cardiometabolic Disorders: Combined Epidemiological and Experimental Evidence

  • Environ Sci Technol. 2025 Mar 4;59(8):3853-3868. doi: 10.1021/acs.est.4c09728.
Qi Jiang 1 Donghui Zhang 1 Naifan Hu 1 Yunfei Ma 2 Huibin Jin 2 Yunhao Zhao 2 Ming Zhang 2 Bin Li 2 Zhenzhen Huang 3 Bifeng Yuan 3 Ying Zhu 1 Jianbo Tian 1 Xiaoping Miao 1
Affiliations

Affiliations

  • 1 Department of Epidemiology and Biostatistics, School of Public Health, Research Center of Public Health, Renmin Hospital of Wuhan University, Department of Gastrointestinal Oncology, Zhongnan Hospital of Wuhan University, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, Hubei 430071, China.
  • 2 Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan 430071, China.
  • 3 Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan 430071, China.
Abstract

Screening environmental pollutants that are harmful to the cardiometabolic status and understanding their key toxic pathways are crucial for effective clinical intervention. Based on exposure data of 46 chemicals in a nationally representative 13,286 people, logistic regression and mixture modeling were used to preliminarily identify environmental pollutants with significant impacts on 12 indicators for cardiometabolic disorders. A total of 15 chemicals were found to be associated with the integrated latent class, among which four chemicals (perfluorononanoic acid [PFNA], perfluorooctanoic acid [PFOA], thiocyanate, and thallium) also contributed significantly to the mixture effect. We constructed the adverse outcome pathways (AOPs) for nine significant toxicants in both models of individual chemicals and the mixture for each cardiometabolic disorder. Notably, fluoroalkyl substances affect multiple aspects of hyperlipidemia by activating PPARα. We performed molecular docking and in vitro experiments to verify and supplement the toxicological mechanism of PFNA. Through binding to PPARα, PFNA increased the levels of downstream molecules including CD36 (fatty acid transfer), ACSL1 (fatty acid activation), and CPT1a (intracellular transfer for β-oxidation) and ultimately promoted the accumulation of triglycerides and lipid droplets in HepG2 cells. These markers, together with key events for Other metabolic phenotypes, may be potential targets for scientific research or clinical treatment.

Keywords

adverse outcome pathway; environmental pollutant; metabolic disease; per- and polyfluoroalkyl substance; peroxisome proliferator-activated receptor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15372
    99.64%, PPAR Antagonist